Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $50.5652W HIGH $392.70
Volume
517.23 K
Value Traded
220.80 M
Short % Float
14.45%
-12.06%Week
-24.74%1 Month
-20.04%3 Month
-17.8%6 Month
+11.24%5 Year
-11.66%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.26 B
EPS (TTM)
-12.15
P/E Ratio
-
Ent. Value
5.88 B
Total Shares
27.92 M
Float Shares
26.26 M
Insiders
5.95%
Institutions
116.64%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PRAX Catalyst Timeline
Dated clinical, regulatory and corporate events for Praxis Precision Medicines, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Praxis Precision Medicines, Inc.
386Total events
11Upcoming
90Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Mid Cycle CommunicationulixacaltamideFiledRegulatory Filing
FDA mid-cycle meeting completed for ulixacaltamide HCl; no major safety or efficacy concerns; no AdCom planned
Essential Tremorsource ↗
▲Mid Cycle CommunicationPRAX-562FiledRegulatory Filing
FDA mid-cycle meeting completed for relutrigine; no major safety or efficacy concerns; no AdCom planned
SCN2A and SCN8A DEEssource ↗
▲Pre Approval InspectionulixacaltamideFiledCMC / Inspection
FDA BIMO inspection completed for ulixacaltamide HCl with no Form 483 issued
Essential Tremorsource ↗
▲Pre Approval InspectionPRAX-562FiledCMC / Inspection
FDA BIMO inspection completed for relutrigine with no Form 483 issued
SCN2A and SCN8A DEEssource ↗
▲Breakthrough Therapy DesignationElsunersenDesignation
FDA granted Breakthrough Therapy Designation to elsunersen based on EMBRAVE Part A results
SCN2A DEEsource ↗
●Major Amendment SubmittedPRAX-562FiledRegulatory Filing
FDA deemed additional sensitivity analyses a major amendment, extending review period for relutrigine NDA
SCN2A and SCN8A DEEssource ↗
▲Enrollment MilestonePRAX-562FiledTrial
EMERALD study enrollment exceeded planned target with approximately 200 patients
DEEssource ↗
▲Partnership / LicenseulixacaltamideFiledCorporate
Strategic collaboration with Remagine Labs to develop transdermal ulixacaltamide
essential tremorsource ↗
▲Partnership / LicenseulixacaltamideFiledCorporate
Strategic collaboration with Remagine Labs to develop transdermal patch of ulixacaltamide
Essential Tremorsource ↗
●Major Amendment SubmittedPRAX-562FiledRegulatory Filing
Submission of additional sensitivity analyses deemed major amendment by FDA
SCN2A and SCN8A developmental and epileptic encephalopathiessource ↗
▲Breakthrough Therapy DesignationElsunersenDesignation
FDA grants Breakthrough Therapy Designation for elsunersen
Seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variantssource ↗
▲Topline ReadoutElsunersenClinical Data
Positive topline results from EMBRAVE Part A: 77% sham-adjusted seizure reduction
Seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variantssource ↗
▲Primary Endpoint MetElsunersenClinical Data
Primary endpoint met: 77% sham-adjusted reduction in monthly seizures
Seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variantssource ↗
▲Enrollment CompleteElsunersenTrial
Enrollment completed in EMBRAVE Part A (9 patients)
Seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variantssource ↗
◆Enrollment UpdateElsunersenTrial
EMBRAVE3 pivotal study is enrolling approximately 30 patients
Seizures associated with SCN2A Developmental and Epileptic Encephalopathy caused by Gain of Function variantssource ↗
▼Primary Endpoint MissedVormatrigineClinical Data
POWER1 did not meet primary endpoint of reduction in monthly focal seizure frequency
Focal Onset Seizuressource ↗
▲Secondary Endpoint DataVormatrigineClinical Data
POWER1 met secondary endpoint of ≥50% reduction in seizure frequency
Focal Onset Seizuressource ↗
▲Safety Data UpdateVormatrigineClinical Data
Vormatrigine generally well-tolerated; AE-related discontinuations <10%
focal onset seizuressource ↗
▲OLE InitiatedVormatrigineTrial
Approximately 90% of vormatrigine arm patients transitioned to and remain in open label extension
focal onset seizuressource ↗
▼Enrollment PausedVormatrigineTrial
Praxis pausing enrollment in POWER2 study to reassess program and determine modifications
focal onset seizuressource ↗
▼Topline ReadoutVormatrigineClinical Data
POWER1 topline results announced; primary endpoint not met, secondary endpoint met
Focal Onset Seizuressource ↗
◆Oral PresentationPresentation
Bank of America Securities Health Care Conference Presentation
◆Poster PresentationElsunersenPresentation
Poster: Complementary ASO treatment and precision NaV modulation for early onset SCN2A-DEE: Emergency use case in preterm infant
SCN2A developmental and epileptic encephalopathysource ↗
◆Poster PresentationVormatriginePresentation
Poster: Vormatrigine Rapidly Reduces Seizures in Adults with Treatment-resistant Epilepsy: Results from RADIANT Study
treatment-resistant epilepsysource ↗
◆Poster PresentationPRAX-562FiledPresentation
Poster: Efficacy and Safety of Relutrigine in Pediatric Participants with SCN2A- and SCN8A-related DEE: Pivotal EMBOLD Cohort 2 Study
SCN2A- and SCN8A-related DEEsource ↗
◆Oral PresentationulixacaltamideFiledPresentation
Plenary presentation of Essential3 topline results at AAN 2026
essential tremorsource ↗
◆Oral PresentationElsunersenPresentation
Clinical updates from elsunersen Emergency Use Program at AAN 2026
SCN2A developmental and epileptic encephalopathysource ↗
◆Poster PresentationPresentation
Poster: High Seizure Burden and Limited Treatment Persistence in Epilepsy: Findings from EMPOWER and US claims analysis
epilepsysource ↗
◆Poster PresentationulixacaltamideFiledPresentation
Poster: Combined Efficacy and Safety of Ulixacaltamide in Essential Tremor: Topline Results from the Phase 3 Essential3 Program
essential tremorsource ↗
◆Oral PresentationulixacaltamideFiledPresentation
Featured oral presentation on digital biomarker pipeline for Essential3
essential tremorsource ↗
▲Breakthrough Therapy DesignationulixacaltamideFiledDesignation
FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor
essential tremorsource ↗
▲FDA Filing AcceptedulixacaltamideFiledRegulatory Filing
FDA accepted ulixacaltamide NDA for essential tremor
essential tremorsource ↗
◆Oral PresentationPresentation
Participation at Oppenheimer 36th Annual Healthcare Conference
▲Management ChangeCorporate
Promotion of Dr. Steven Petrou to President of Research & Development
●Timing GuidanceulixacaltamideFiledPresentation
NDA submission for ulixacaltamide expected in early 2026
essential tremorsource ↗
◆Topline ReadoutElsunersenClinical Data
Topline results from EMBRAVE Part A (n=9) expected in first half of 2026
early-onset SCN2A developmental and epileptic encephalopathysource ↗
◆NDA SubmissionPRAX-562FiledRegulatory Filing
NDA submission for relutrigine in SCN2A and SCN8A DEE
SCN2A and SCN8A Developmental and Epileptic Encephalopathiessource ↗
◆Trial InitiationVormatrigineTrial
POWER3 monotherapy study on track to begin in 1H 2026
Focal Onset Seizuressource ↗
◆Topline ReadoutPRAX-562FiledClinical Data
Topline results from EMBOLD cohort 2 expected no later than H1 2026
SCN2A and SCN8A developmental and epileptic encephalopathiessource ↗
◆Topline ReadoutVormatrigineClinical Data
Topline results from second efficacy study in focal onset seizures
focal onset seizuressource ↗
▲Breakthrough Therapy DesignationulixacaltamideFiledDesignation
FDA granted Breakthrough Therapy Designation for ulixacaltamide in essential tremor
essential tremorsource ↗
Past FDA Catalysts and PDUFA Decisions
How PRAX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | Vormatrigine | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C54 / 100
Pipeline Score
$823M
Pipeline Value
Richly Valued
Valuation Signal
7
Drugs Scored
0.1x
rNPV / MCap
Top 12%
Small Cap(rank 80 of 658)
Percentile Rank
Praxis Precision Medicines, Inc. carries a moderate pipeline score (54/100), with $1.3B risk-adjusted pipeline value, led by Vormatrigine in Epilepsy, Tonic-Clonic (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vormatrigine Small moleculeNCT07287163 | Epilepsy, Tonic-Clonic | Phase 3 | ENROLLING BY_INVITATION | 700 | Dec 31, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every PRAX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| vormatrigine | focal onset seizures | Phase 2/3 | 2026-06-02 | 50% response rate; less than 10% adverse event-related discontinuations; approximately 90% of patients transitioned to OLE studyRead More | Praxis Precision Medicines Provides Vormatrigine Program UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Souza MarcioDirector, Officer (Chief Executive Officer) | Disposition | -20,521 56,495 held | $0.00 | 07/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PRAX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10.2 % (-20.3 %) | 681.63 M | 2.04 M |
PRAX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRAX ranks across every disease it competes in
Competitive Position is a premium feature
See how PRAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRAX News
PRAXPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. has announced the granting of restricted stock unit awards to fourteen new non-executive employees as part of its 2024 Inducement Plan. This initiative aims to attract talent in line with Nasdaq Listing Rule 5635(c)(4). The awards will vest over four years, contingent on continued employment.
Read more →PRAX▲ +16%on this news
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Praxis Precision Medicines provided a corporate update and reported its second quarter 2026 financial results. The FDA has completed mid-cycle meetings for ulixacaltamide and relutrigine, identifying no major safety or efficacy concerns. Praxis also received a third Breakthrough Therapy Designation for elsunersen. Despite a net loss increase, the company maintains a strong cash position to support ongoing operations.
Read more →PRAXPraxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Praxis Precision Medicines will report its financial results for Q2 2026 on August 6, 2026. The company will also provide a corporate update during a conference call at 8:30 am ET. Investors can access the live webcast through the company's website, with a replay available for 90 days afterward.
Read more →PRAXPraxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
Praxis Precision Medicines and Remagine Labs have announced a strategic collaboration to develop a transdermal delivery system for ulixacaltamide, aimed at treating essential tremor. This partnership seeks to broaden the drug's market reach and enhance its competitive positioning. Praxis has made an equity investment in Remagine, emphasizing their commitment to the collaboration as they prepare for ulixacaltamide's FDA review.
Read more →PRAXPraxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Praxis Precision Medicines announced an extension of the FDA review period for relutrigine, now set for December 27, 2026. The extension follows the submission of additional analyses deemed a major amendment. No new clinical studies were requested, and the company remains confident in its application to address significant unmet needs in SCN2A and SCN8A developmental and epileptic encephalopathies.
Read more →PRAX▲ +7.5%on this news
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
Praxis Precision Medicines has received FDA Breakthrough Therapy Designation for elsunersen, an antisense oligonucleotide aimed at treating seizures linked to SCN2A Developmental and Epileptic Encephalopathy. The designation follows positive results from the EMBRAVE Part A trial, which demonstrated a significant reduction in seizures among treated patients. Elsunersen is now positioned for expedited development, reflecting its potential as a first disease-modifying therapy for this condition.
Read more →PRAX▼ -5.1%on this news
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
Read more →PRAX▲ +8.1%on this newsshared move
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Praxis Precision Medicines, Inc. has granted restricted stock unit awards to thirteen new non-executive employees as part of its 2024 Inducement Plan. This initiative, compliant with Nasdaq Listing Rule 5635(c)(4), aims to attract talent by offering equity awards. The units will vest annually over four years, contingent on continued employment.
Read more →PRAX▼ -23%on this newsshared move
Praxis Precision Medicines Provides Vormatrigine Program Update
Praxis Precision Medicines announced mixed results from the Phase 2/3 POWER1 study of vormatrigine for focal onset seizures. While the primary endpoint was not achieved, the secondary measure showed promise with a 50% response rate and better seizure reduction at higher doses. The company is pausing enrollment in the POWER2 study to evaluate the program further.
Read more →PRAXPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
Read more →PRAXPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2026
Praxis Precision Medicines, Inc. announced the granting of restricted stock unit awards to 21 new non-executive employees as part of its 2024 Inducement Plan. This initiative is designed to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The stock units will vest over four years, contingent on continued employment.
Read more →PRAXPraxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
Praxis Precision Medicines will report its Q1 2026 financial results on May 7, 2026, and provide a corporate update. The company will also participate in the Bank of America Securities Health Care Conference on May 12, 2026. The live webcast of both events will be accessible through their website.
Read more →PRAX▲ +8.4%on this news
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Read more →PRAXPraxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
Praxis Precision Medicines announced the presentation of its Phase 3 Essential3 program results for ulixacaltamide at the AAN 2026 Annual Meeting. This program is notable for being the first positive Phase 3 trial in essential tremor, a condition affecting millions. The company will showcase its findings through multiple presentations and discussions at the event.
Read more →PRAXPraxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Read more →PRAXPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026
Praxis Precision Medicines, Inc. announced the granting of restricted stock unit awards to eighteen new non-executive employees as part of its 2024 Inducement Plan. This initiative, in accordance with Nasdaq Listing Rule 5635(c)(4), aims to incentivize new hires. The awards will vest over four years, contingent on continued employment.
Read more →PRAXPraxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Read more →About Praxis Precision Medicines, Inc.
Headquarters99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110
BIOPHARMAWATCH ELITE PLUS
Trade the next PRAX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime